Doximity AI Safety Study Validates Clinical Platform, Bolstering Bull Case

What happened

Doximity announced that its HIPAA-compliant clinical AI platform, Ask, outperformed leading frontier models in the NOHARM benchmark, an independent clinical AI safety study led by Stanford and Harvard researchers. This third-party validation strengthens Doximity's positioning in the increasingly competitive AI-powered clinical workflow space, where the company has been a late entrant with its free AI scribe tool. The report highlights Doximity's strong financials, with FY2025 revenue of $570 million and adjusted EBITDA of $314 million, plus a net cash position of ~$916 million supporting buybacks. However, the crowded AI scribe market, pharma budget sensitivity, and ongoing securities lawsuits remain key risks to monitor. Current valuation (EV/EBITDA ~13x) offers reasonable entry with ~38% DCF upside, but sustained reacceleration from AI monetization is needed to upgrade to Strong Buy.

Implication

If Doximity leverages this differentiation to drive adoption and monetization of its AI workflow tools, it could expand margins and revenue growth, supporting a higher valuation. However, the crowded market and regulatory overhangs require close monitoring.

Thesis delta

The independent study shifts the narrative from Doximity being a late entrant in AI scribe to a validated leader in clinical AI safety, potentially accelerating adoption and revenue from workflow solutions. This could upgrade the thesis from POSSIBLE BUY to STRONG BUY if follow-through materializes in upcoming quarters, but watch for execution against guidance and legal outcomes.